Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Earnings Call Summary
AstraZeneca Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 58.74B | 52.94B | 46.58B | 44.25B | 37.11B |
| Gross Profit | 48.11B | 39.70B | 34.45B | 28.04B | 22.60B |
| EBITDA | 19.83B | 14.86B | 13.20B | 8.63B | 4.59B |
| Net Income | 10.22B | 6.89B | 6.06B | 3.28B | 109.85M |
Balance Sheet | |||||
| Total Assets | 114.07B | 104.03B | 101.12B | 96.48B | 105.36B |
| Cash, Cash Equivalents and Short-Term Investments | 5.74B | 5.65B | 5.91B | 6.24B | 6.37B |
| Total Debt | 29.62B | 30.11B | 28.41B | 29.14B | 30.69B |
| Total Liabilities | 65.36B | 63.16B | 61.95B | 59.42B | 66.08B |
| Stockholders Equity | 48.67B | 40.79B | 39.14B | 37.04B | 39.27B |
Cash Flow | |||||
| Free Cash Flow | 8.67B | 7.28B | 6.57B | 7.24B | 3.76B |
| Operating Cash Flow | 14.57B | 11.86B | 10.35B | 9.81B | 5.96B |
| Investing Cash Flow | -6.81B | -7.98B | -4.06B | -2.96B | -11.06B |
| Financing Cash Flow | -7.54B | -4.00B | -6.57B | -6.82B | 3.65B |
AstraZeneca Technical Analysis
AstraZeneca Risk Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £213.12B | 28.13 | 23.00% | 1.53% | 10.20% | 40.57% | |
70 Outperform | £10.08B | 22.64 | 11.79% | 2.35% | 2.51% | 56.56% | |
69 Neutral | £77.48B | 12.93 | 37.19% | 3.29% | 2.73% | 119.38% | |
67 Neutral | £4.24B | 37.08 | 10.53% | 2.11% | 4.18% | 37.65% | |
59 Neutral | £2.67B | 11.21 | 15.83% | 4.16% | 3.73% | 27.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
AstraZeneca Corporate Events
AstraZeneca has admitted 45,750 additional ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market, bringing the total number of shares in issue to 1,550,980,332. The new shares, which are fully fungible with existing ordinary shares, were issued between 20 January and 19 March 2026 under the company’s pre-existing block admission.
These shares were created to satisfy awards under AstraZeneca’s employee share schemes and did not require a new prospectus, reflecting routine equity issuance rather than a capital-raising transaction. The move modestly increases the company’s share count but primarily underscores AstraZeneca’s ongoing use of equity-based compensation to align employees with long-term shareholder interests.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £240.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has secured European Union approval for its immunotherapy Imfinzi, in combination with standard FLOT chemotherapy, as the first perioperative immunotherapy regimen for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. The decision, based on the Phase III MATTERHORN trial, further consolidates the company’s position in early-stage oncology and broadens Imfinzi’s role as a backbone therapy across solid tumours.
The MATTERHORN data showed that adding Imfinzi to chemotherapy reduced the risk of disease progression, recurrence or death by 29% and cut the risk of death by 22% versus chemotherapy alone, with survival benefits increasing over time and observed regardless of PD-L1 status. With a safety profile consistent with existing uses and similar surgery completion rates, the regimen is expected to become a new standard of care in Europe, strengthening AstraZeneca’s competitive footing in gastrointestinal cancer and complementing approvals already granted in the U.S. and other markets, while additional regulatory reviews continue globally.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16496.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has published the notice and shareholders’ circular for its 2026 Annual General Meeting, which will be digitally enabled and held on 9 April 2026 at 14:30 BST. The documents, including the proxy form and updated 2020 Performance Share Plan rules, have been filed with the UK National Storage Mechanism and are available on the company’s website.
Shareholders will vote on routine but strategically important items, including approval of 2025 accounts and dividends, re-election of directors, auditor appointment, and multiple capital authorities such as share allotment, pre-emption disapplication and share buybacks. The notice also sets record dates and participation rules for holders across the UK, US and Swedish markets, underscoring AstraZeneca’s broad international investor base and governance framework.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £180.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca disclosed that Chief Executive Officer Pascal Soriot received an allocation of 101,495 ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan. The award, originally granted in March 2021 with a three-year performance period and subsequent two-year holding period, vested at 88% of the maximum based on performance conditions, with shares delivered for nil consideration and a portion withheld to cover tax obligations.
The transaction, conducted outside a trading venue on 5 March 2026, increases Soriot’s beneficial interest in AstraZeneca stock and underscores the company’s continued reliance on performance-based equity to align executive compensation with shareholder returns. The fair market value used for tax purposes was set at 15,088 pence per share, reflecting the closing price on the last trading day before vesting and signalling the significant value of long-term incentives tied to AstraZeneca’s share performance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £180.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has reported that deferred share awards granted in March 2023 under its AstraZeneca Deferred Bonus Plan have vested for senior executives, following the completion of a three-year holding period tied to 2022 performance. Chief executive Pascal Soriot acquired 14,967 ordinary shares and chief financial officer Aradhana Sarin received 4,863 shares, after dividend reinvestment and tax-related withholdings, at a fair market value of 14,932 pence per share for tax purposes.
The transactions, conducted for nil consideration and outside a trading venue, increase the executives’ beneficial interests in the company and reinforce AstraZeneca’s pay-for-performance alignment between management and shareholders. The disclosure, made in line with EU Market Abuse Regulation requirements as incorporated into U.K. law, provides investors with additional transparency on insider equity holdings at the FTSE-listed drugmaker.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £180.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has granted share awards to Chief Executive Officer Pascal Soriot and Chief Financial Officer Aradhana Sarin under its Deferred Bonus Plan and Performance Share Plan, aligning a portion of their 2025 bonuses and long-term incentives with company equity. Soriot received a total of 103,581 ordinary shares and Sarin 42,393 shares at an award price of £152.42, with vesting and holding periods tied to multi-year performance metrics.
The deferred bonus awards will vest after three years, while performance share awards are subject to a three-year performance assessment focused on scientific, commercial, financial, and sustainability outcomes, followed by a two-year holding period. This structure reinforces long-term alignment between executive rewards, the company’s strategic priorities, and shareholder interests, and complies with UK market abuse and disclosure regulations.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £180.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has tapped the debt markets through its subsidiary AstraZeneca Finance LLC, pricing a three-tranche global bond offering totalling $2bn, with maturities in 2031, 2033 and 2036 and fixed coupons ranging from 4.000% to 4.600%. The proceeds will be used for general corporate purposes, potentially including refinancing existing debt, and the company stated the issuance will not affect its financial guidance for 2026, suggesting a routine balance sheet management move rather than a shift in its near-term outlook.
The notes are fully and unconditionally guaranteed by AstraZeneca and issued under an existing SEC-registered shelf, with BofA Securities, Deutsche Bank Securities, HSBC Securities (USA) and Mizuho Securities USA acting as joint bookrunners. By maintaining access to global capital markets on standard terms, AstraZeneca reinforces its funding flexibility and supports ongoing investment capacity without signalling changes to its core operational or earnings trajectory.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £176.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has filed its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, making the document available on both the regulator’s and the company’s websites. The company is also offering hard copies of its complete audited financial statements free of charge to security holders upon request, underlining its ongoing disclosure obligations to investors and regulators.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16781.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has published its 2025 Annual Report and Form 20-F Information, making the document available via the U.K. National Storage Mechanism and on the company’s website, with hard copies to be dispatched to shareholders in due course. The filing, prepared to meet disclosure and transparency requirements, includes unedited details on principal risks and uncertainties, directors’ responsibility statements and related-party transactions, ahead of the company’s annual general meeting scheduled for 9 April 2026, underscoring its ongoing regulatory compliance and governance transparency for investors and other stakeholders.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16781.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced changes to its non-executive board, with long-serving director Nazneen Rahman set to retire at the conclusion of the company’s annual general meeting on 9 April 2026, ending a tenure that began in 2017 and included leadership roles across key board committees. The company said that at the same AGM, Tony Mok will take over as chair of the Sustainability Committee and join the Nomination and Governance Committee, while Birgit Conix will become a member of the Sustainability Committee, signalling continued emphasis on governance and sustainability oversight.
Chair Michel Demaré praised Rahman’s contributions, highlighting her expertise in genetics research, sustainable healthcare and open science, and her service as chair of the Science Committee from 2017 to 2023 and of the Sustainability Committee since its creation in 2021. The refreshed committee structure underscores AstraZeneca’s intent to maintain strong scientific and sustainability credentials at board level, a move that may reassure investors and stakeholders focused on long-term governance, ESG performance and strategic oversight of the company’s research-driven portfolio.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16781.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has secured U.S. FDA approval for Calquence (acalabrutinib) in combination with venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma. The 14-month combination is intended to offer an effective, time-limited alternative to continuous treatment, giving physicians more flexibility to align therapy with patient needs.
The approval is backed by the Phase III AMPLIFY trial, where the Calquence plus venetoclax regimen showed a statistically significant progression-free survival benefit over standard chemoimmunotherapy, with 77% of patients progression-free at three years versus 67% on chemotherapy. Safety was consistent with the known Calquence profile, and the regimen, already cleared in Europe, Canada, the U.K. and other markets, is expected to strengthen AstraZeneca’s competitive position in first-line CLL and support its broader push to redefine care in B‑cell blood cancers.
AstraZeneca is also developing Calquence further as a single agent and in combinations across multiple B‑cell malignancies, including mantle cell lymphoma and diffuse large B‑cell lymphoma. The expanded label in the U.S., alongside ongoing global regulatory reviews, underscores the company’s strategy to build a leading haematology franchise and may increase uptake of its BTK inhibitor-based regimens in a large and growing CLL population.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16781.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has entered a strategic collaboration with China’s CSPC Pharmaceuticals to expand its weight management portfolio, securing exclusive rights outside China to CSPC’s once‑monthly injectable obesity and type 2 diabetes therapies, including a Phase I‑ready long‑acting GLP1R/GIPR agonist and three preclinical assets. The agreement, which also grants AstraZeneca access to CSPC’s AI‑driven peptide discovery platform and LiquidGel once‑monthly dosing technology, is structured around an upfront payment of $1.2 billion plus up to $3.5 billion in development and regulatory milestones and additional commercial payments, and is expected to strengthen AstraZeneca’s competitive position in the fast‑growing obesity market by complementing its existing pipeline of next‑generation weight management drugs while potentially improving patient adherence through simplified, sustained‑release regimens.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca will invest $15 billion in China through 2030 to expand its research, development and manufacturing footprint, deepening its presence in advanced modalities such as cell therapy and radioconjugates and reinforcing China’s role as a strategic hub in its global pipeline. The landmark programme, announced during the UK Prime Minister’s visit to China, aims to build end‑to‑end cell therapy capabilities, upgrade and add manufacturing sites, expand its Chinese workforce beyond 20,000, and strengthen China‑UK life sciences collaboration, positioning the company to accelerate innovative drug development and broaden patient access in China while supporting jobs and research ecosystems in both countries.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £163.89 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca will voluntarily withdraw the listing of its American Depositary Shares and certain US dollar-denominated debt securities from Nasdaq as it completes a direct listing of its ordinary shares and all US debt securities on the New York Stock Exchange after market close on 30 January 2026. The move forms part of a shareholder-approved plan to harmonise the company’s share listing structure, creating a unified global platform that allows investors to trade AstraZeneca’s ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE under the unchanged ticker AZN, and is intended to simplify access for global investors and support the company’s positioning as a globally traded biopharmaceutical leader.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £110.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has appointed Joris Silon as Head of Investor Relations, effective 1 March 2026, succeeding Andy Barnett and based in Cambridge, UK. Silon moves into the role from his position as country president of AstraZeneca US, where he oversaw significant growth in the company’s largest market, bringing more than two decades of global leadership experience across Asia, Europe and the US. The appointment underscores AstraZeneca’s focus on strengthening its engagement with the investment community as it enters a new phase of growth, while Barnett transitions to another senior role within the company, maintaining continuity in its investor relations strategy and leadership.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has confirmed that, as of 31 December 2025, its issued share capital with voting rights consists of 1,550,907,927 ordinary shares, with no shares held in treasury, establishing the total number of voting rights at the same figure. This disclosure, made under UK Financial Conduct Authority transparency rules, provides shareholders and market participants with the reference denominator needed to assess and report any holdings or changes in holdings, supporting regulatory compliance and ensuring clarity around AstraZeneca’s equity base and governance structure.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.